Watch VSBC. Know when insiders buy.
One email the day a filing lands. Free.
VSBC
VITASPRING BIOMEDICAL CO. LTD.
0.01
+0.00 +0.00%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.3MP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$456KNET CASH —52W 0.01 – 1.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2027 · Jul 31 | $0 | — | — | −$162K | −$156K | — | 0.00 | $5K | — | — | Sep 17 |
| Q1 2027 · Apr 30 | $0 | — | — | −$76K | −$76K | — | 0.00 | $6K | — | — | Sep 17 |
| Q4 2026 · Jan 31derived | $0 | — | — | −$81K | −$81K | — | 0.00 | $124 | — | — | Jun 17 |
| Q3 2026 · Oct 31 | $0 | — | — | −$136K | −$143K | — | 0.00 | −$839 | — | — | Jun 17 |
| Q2 2026 · Jul 31 | $0 | — | — | −$99K | −$111K | — | 0.00 | −$1K | — | — | Sep 17 |
| Q1 2026 · Apr 30 | $0 | — | — | −$69K | −$81K | — | 0.00 | −$787 | — | — | Sep 17 |
| Q4 2025 · Jan 31derived | $0 | — | — | −$126K | −$143K | — | 0.00 | −$2K | — | — | Jun 17 |
| Q3 2025 · Oct 31 | $0 | — | — | −$118K | −$196K | — | 0.00 | −$6K | — | — | Jun 17 |
| Q2 2025 · Jul 31 | $0 | — | — | −$219K | −$219K | — | 0.00 | −$2K | — | — | Jun 17 |
| Q1 2025 · Apr 30 | $0 | — | — | −$217K | −$217K | — | 0.00 | −$4K | — | — | Jun 17 |
| Q4 2024 · Jan 31derived | $0 | — | — | −$225K | −$225K | — | -0.01 | −$3K | — | — | Jun 8 |
| Q3 2024 · Oct 31 | $0 | — | — | −$235K | −$235K | — | 0.00 | −$5K | — | — | May 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jan 31 | $0 | — | −$385K | −$415K | — | 0.00 | −$3K | — | — | — | — |
| FY2025 · to Jan 31 | $0 | — | −$680K | −$775K | — | 0.00 | −$15K | — | — | — | — |
| FY2024 · to Jan 31 | $0 | — | −$1.1M | −$1.1M | — | -0.01 | −$35K | — | — | — | — |
| FY2023 · to Jan 31 | $0 | — | −$4.2M | −$4.2M | — | -0.02 | −$78K | $0 | −$78K | — | — |
| FY2022 · to Jan 31 | $5.6M | 36.8% | $1.1M | $910K | 16.2% | 0.00 | −$270K | $73K | −$343K | — | — |
| FY2021 · to Jan 31 | $248K | 45.2% | $425K | $425K | 171.4% | 0.00 | −$42K | — | — | — | — |
Every number comes from VITASPRING BIOMEDICAL CO. LTD.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.